pz1

Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks the blood supply required for RET-stimulated growth.

PZ15527 is a PROTAC that targets Bcl-xl.

PPZ1 is a novel DAG-activated TRPC3/TRPC6/TRPC7 channels activator.

PZ-1922 free base is a brain-penetrant 5-HT6R/5-HT3R antagonist with Ki values of 17 nM and 0.45 nM, respectively. It reversibly inhibits MAO-B (pIC50: 8.93). In rat novel object recognition (NOR) tests, PZ-1922 free base counteracts Scopolamine (SCOP)-induced memory deficits and prevents Aβ-induced memory decline in T-maze tests.

PZ-128, a PAR1 antagonist, is used potentially for the treatment of thrombosis.

PZ-1922 (Compound 16), able to cross the blood-brain barrier, is a dual antagonist for 5-HT6R and 5-HT3R with K i values of 17 nM and 0.45 nM, respectively. It also reversibly inhibits MAO-B with a pIC50 of 8.93. Moreover, PZ-1922 mitigates scopolamine (SCOP)-induced memory deficits in rats as observed in the novel object recognition (NOR) test and hinders Aβ-induced memory impairment in the T-maze test [1].

PZ-1190, a multitarget ligand for serotonin and dopamine receptors, exhibits potential antipsychotic activity in rodents [1].